PhotoPharmics

About:

PhotoPharmics is a clinical-stage medical device company developing next-generation treatments for treating neurodegenerative disorders.

Website: http://photopharmics.com

Twitter/X: photopharmics

Top Investors: Kickstart, PC Squared, LLC

Description:

PhotoPharmics is a clinical-stage medical device company developing next-generation treatments for treating neurodegenerative disorders through the eyes. We have 30+ years of research and experience in specialized phototherapy. We previously developed specialized solutions now widely used to regulate circadian rhythms for seasonal affective disorder, sleep disorders, anxiety, and depression (acquired by Philips-Respironics in 2007). We are currently extending our research into several other neurodegenerative diseases. We aim to make a clinically meaningful difference in patients’ lives by delivering safe and effective treatments.

Total Funding Amount:

$31.9M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

American Fork, Utah, United States

Founded Date:

2011-01-01

Contact Email:

info(AT)photopharmics.com

Founders:

Daniel Adams, Kent Savage

Number of Employees:

1-10

Last Funding Date:

2023-11-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai